Dr. Reddy’s Lab’s Q2FY25Results
Dr. Reddy’s Lab’s revenue grew 16% YoY
- 07 Nov 2024
Read Full Article >
- Dr. Reddy’s Lab reported a 6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter ended Sept (Q2FY25). On a year-on-year (YoY) basis, it witnessed a growth of 16%.
- Its expenses for the quarter were up by 7% QoQ and 21% YoY.
- The net profit declined 4% QoQ and 9% YoY.
- The earnings per share (EPS) of Dr. Reddy’s Lab stood at 15.1 during Q2FY25.
Dr. Reddy’s Lab’s Financial Statements for Q2FY25:
| (₹, crores) | Q2FY24 | Q1FY25 | Q2FY25 | QoQ (%) | YoY (%) |mobile_heder |
|---|---|---|---|---|---|
Total income | 7,218 | 7,883 | 8,346 | 6% | 16% |
Total expenses | 5,305 | 6,007 | 6,434 | 7% | 21% |
Profit before tax | 1,917 | 1,883 | 1,917 | 2% | 0.04% |
Tax | 435 | 490 | 576 | 17% | 32% |
Profit after tax | 1,482 | 1,392 | 1,342 | -4% | -9% |
Earnings per share | 17.8 | 16.7 | 15.1 |
Financials:
Revenues: ₹80,162 Mn, up 17% YoY, 4% QoQ.
Gross Margin: 59.6%, higher than Q2FY24’s 58.7% but lower than Q1FY25’s 60.4%.
SG&A Expenses: ₹23,007 Mn, up 22% YoY, 1% QoQ.
R&D Expenses: ₹7,271 Mn, constituting 9.1% of revenues.
EBITDA: ₹22,803 Mn, representing 28.4% of revenues.
Profit before Tax: ₹19,167 Mn, flat YoY, up 2% QoQ.
Profit after Tax (before Non-Controlling Interest): ₹13,415 Mn, down 9% YoY, 4% QoQ.
Profit after Tax (attributable to Equity Holders): ₹12,553 Mn, down 15% YoY, 10% QoQ.
Management Commentary:
Co-Chairman & MD, G V Prasad:
- Achieved strong growth and maintained business momentum.
- Progressed on future growth drivers.
- Operationalised a venture with Nestlé.
- Completed the acquisition of Nicotinell® and related brands.
- Committed to enhancing efficiency and strengthening core businesses.
- Focused on positively impacting patient lives through science and innovation.
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Open Demat Account
